204 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
8 Jan 24
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
6:30am
NSCLC Non - small cell lung cancer ORR Overall Response Rate OTOF Otoferlin PBO Placebo PD - 1/PD - (L)1 Programmed cell death protein/(ligand) 1 PDUFA
SC TO-T
EX-99
aeanu
25 Aug 23
Third party tender offer statement
7:46am
SC TO-T
EX-99
30pdlg lia
25 Aug 23
Third party tender offer statement
7:46am
8-K
EX-99.1
4a0aulyjh
3 Aug 23
Regeneron Reports Second Quarter 2023 Financial and Operating Results
6:48am
8-K
EX-10.1
ei19mazx1gwu0y2o
29 Mar 23
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.2
5vbr4x1f bng
29 Mar 23
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.1
ua4hxiah57bf
20 Dec 22
Entry into a Material Definitive Agreement
4:01pm
SC TO-T
EX-99
t14300ptg xa2g8v215
2 May 22
Third party tender offer statement
7:48am
SC TO-T
EX-99
l4hnx xll1v
2 May 22
Third party tender offer statement
7:48am
DEFA14A
6hdc314mi3nkcc
21 Apr 22
Additional proxy soliciting materials
4:21pm
8-K
EX-10.3
2fgoopug8kif4tfgae
8 Mar 22
Entry into a Material Definitive Agreement
6:15am